RO 262198

Drug Profile

RO 262198

Latest Information Update: 01 Jun 2007

Price : $50

At a glance

  • Originator BioXell Inc; BioXell SpA
  • Class Antihyperglycaemics; Cyclohexanes; Hydroxycholecalciferols
  • Mechanism of Action Vitamin D3 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Type 1 diabetes mellitus

Most Recent Events

  • 09 Dec 2005 Suspended - Preclinical for Type-1-diabetes-mellitus in Italy (unspecified route)
  • 09 Dec 2005 Suspended - Preclinical for Type-1-diabetes-mellitus in USA (unspecified route)
  • 28 May 2002 Preclinical trials in Type-1 diabetes mellitus in Italy (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top